Amgen and Cap Gemini vary Europe bond roadshow menu
Amgen and Cap Gemini both announced roadshows to European bond investors this week. Amgen, the US biotechnology company rated Baa1/A+/BBB, all with stable outlooks, will make a rare visit by a transatlantic issuer.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts